Back to Search Start Over

Immune interaction between SARS-CoV-2 and Mycobacterium tuberculosis .

Authors :
Booysen P
Wilkinson KA
Sheerin D
Waters R
Coussens AK
Wilkinson RJ
Source :
Frontiers in immunology [Front Immunol] 2023 Sep 27; Vol. 14, pp. 1254206. Date of Electronic Publication: 2023 Sep 27 (Print Publication: 2023).
Publication Year :
2023

Abstract

SARS-CoV-2 and Mycobacterium tuberculosis ( Mtb ) are major infectious causes of death, with meta-analyses and population-based studies finding increased mortality in co-infected patients simultaneously diagnosed with COVID-19 and tuberculosis (TB). There is a need to understand the immune interaction between SARS-CoV-2 and Mtb which impacts poor outcomes for those co-infected. We performed a PubMed and preprint search using keywords [SARS-CoV-2] AND [tuberculosis] AND [Immune response], including publications after January 2020, excluding reviews or opinions. Abstracts were evaluated by authors for inclusion of data specifically investigating the innate and/or acquired immune responses to SARS-CoV-2 and Mtb in humans and animal models, immunopathological responses in co-infection and both trials and investigations of potential protection against SARS-CoV-2 by Bacille Calmette Guérin (BCG). Of the 248 articles identified, 39 were included. Incidence of co-infection is discussed, considering in areas with a high burden of TB, where reported co-infection is likely underestimated. We evaluated evidence of the clinical association between COVID-19 and TB, discuss differences and similarities in immune responses in humans and in murine studies, and the implications of co-infection. SARS-CoV-2 and Mtb have both been shown to modulate immune responses, particularly of monocytes, macrophages, neutrophils, and T cells. Co-infection may result in impaired immunity to SARS-CoV-2, with an exacerbated inflammatory response, while T cell responses to Mtb may be modulated by SARS-CoV-2. Furthermore, there has been no proven potential COVID-19 clinical benefit of BCG despite numerous large-scale clinical trials.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Booysen, Wilkinson, Sheerin, Waters, Coussens and Wilkinson.)

Details

Language :
English
ISSN :
1664-3224
Volume :
14
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
37841282
Full Text :
https://doi.org/10.3389/fimmu.2023.1254206